

U.S. Revenue Cycle Management for Oncology And Urology Market Size, Share & Trends Analysis Report By Sourcing (In-house, External RCM Apps/ Software, Outsourced RCM Services), By End Use, And Segment Forecasts, 2023 - 2030

https://marketpublishers.com/r/UCF79A6250CBEN.html

Date: November 2022

Pages: 68

Price: US\$ 3,500.00 (Single User License)

ID: UCF79A6250CBEN

Abstracts

This report can be delivered to the clients within 2 Business Days

U.S. Revenue Cycle Management For Oncology And Urology Market Growth & Trends

The U.S. revenue cycle management for oncology and urology market is expected to reach USD 22.3 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 13.7% from 2023 to 2030. The market growth can be attributed to the rising adoption of applications that would help in streamlining revenue cycles for various healthcare institutions and technological advancements undertaken by the key players in the market.

Developers and vendors of RCM platforms & solutions are supporting healthcare facilities in accommodating and getting themselves accustomed to the transitions associated with ICD-10. RCM providers are focusing on increasing staff resources & providing adequate training sources and improving customer engagement. For instance, in January 2020, OnQ launched Robotic Process Automation (RPA). The company's accessible RPA solutions considerably helped in enhancing service quality, improving efficiencies, and shortening medical billing procedures.

According to The State of RPA in the Revenue Cycle survey conducted in 2021, 51% of the healthcare systems in the U.S. are widely adopting Robotic Process Automation (RPA) in improving their RCM platforms. RPA and automation allow to streamline and



simplify various aspects of the RCM solution that is repetitive, manual, or rule-based. The survey further states that midsized and large-sized hospitals are using automation across all functions of their RCM platform. The top five RCM processes wherein automation is widely being used are Eligibility (59%), Authorization (57%), Claims/Follow-up (43%), Charge Capture (39%), and Payments/Collections (39%).

Increasing adoption of RCM outsourcing in the U.S. is expected to positively impact the growth of the market during the forecast period. The changing aspects of RCM outsourcing are mainly due to the availability of finances, value addition, and business prospects. Moreover, due to awareness regarding cost savings with respect to the adoption of RCM solutions, efficient and cost-effective services are some of the major advantages of RCM outsourcing. Despite this, the shortage of skilled professionals required for managing the revenue cycle management software is expected to restrain the growth of the market over the forecast period.

U.S. Revenue Cycle Management For Oncology And Urology Market Report Highlights

In 2022, in house segment held the largest share of 72.9%. Higher adoption of in-house RCM software due to flexibility in the functioning of the software is one of the significant factors contributing to segmental growth.

In 2022, the hospital segment held the largest share of 58.6% due to the rising adoption of RCM solutions to manage the financial aspects of the hospitals.

The key players in the market have been involved in mergers and acquisitions to increase their share in the market and provide innovative solutions to the endusers which is anticipated to boost the market growth during the forecast period.



Contents

CHAPTER 1 METHODOLOGY AND SCOPE

- 1.1 Market Segmentation and Scope
- 1.2 Research Process
 - 1.2.1 Information Procurement
 - 1.2.1.1 Purchased Database
 - 1.2.1.2 GVR's Internal Database
 - 1.2.2 Primary Research
- 1.3 Research Methodology for Parent Market (U.S. RCM Market)
 - 1.3.1 Company Market Share
 - 1.3.2 Market Estimations
 - 1.3.2.1 RCM Market Estimation
 - 1.3.2.2 RCM Outsourcing Market Estimation
 - 1.3.2.3 In-House U.S. RCM Market Estimation
 - 1.3.2.4 U.S. RCM Market Estimation
 - 1.3.2.5 Oncology And Urology Practices in the U.S. estimation
 - 1.3.3 Country Market: CAGR Calculation
- 1.4 Country-based Segment Share Calculation
 - 1.4.1 Segmental Market Estimation for Oncology and Urology:
- 1.5 List of Data Sources

CHAPTER 2 EXECUTIVE SUMMARY

- 2.1 Market Snapshot
- 2.2 Segment Snapshot
- 2.3 Competitive Landscape Snapshot

CHAPTER 3 U.S. REVENUE CYCLE MANAGEMENT FOR ONCOLOGY AND UROLOGY MARKET VARIABLES, TRENDS & SCOPE

- 3.1 U.S. Revenue Cycle Management for Oncology and Urology Market Snapshot
- 3.2 Penetration and Growth Prospect Mapping
- 3.3 Market Dynamics
 - 3.3.1 Market Driver Analysis
 - 3.3.1.1 Technological Advancements
 - 3.3.1.2 Increase in outsourcing of RCM
 - 3.3.1.3 Increasing adoption of mHealth



- 3.3.1.4 Growth of High-Deductible Health Plans (Hdhps)
- 3.3.2 Market Restraint Analysis
- 3.3.2.1 Increasing Payer Partnerships
- 3.3.2.2 Lack Of Professionals To Handle RCM Processes
- 3.4 U.S. Revenue Cycle Management Market Analysis Tools
 - 3.4.1 Industry Analysis Porter's Five Forces
 - 3.4.1.1 Bargaining Power Of Suppliers-Moderate
 - 3.4.1.2 Bargaining Power Of Buyers- Moderate
 - 3.4.1.3 Threat Of Substitution- Low
 - 3.4.1.4 Threat Of New Entrants- Moderate
 - 3.4.1.5 Competitive Rivalry- High
- 3.5 Number of Oncology and Urology Practices in the U.S.
 - 3.5.1 Estimated total number of oncology hospitals & practices, 2021
 - 3.5.2 Estimated total number of oncology hospitals & practices, 2021, By Size
 - 3.5.3 Estimated total number of urology hospitals & practices, 2021
- 3.6 Penetration Rates of In-house vs Outsourced RCM Services for Oncology
 - 3.6.1 Community Practices
 - 3.6.2 Hospitals
- 3.7 Penetration Rates of In-house vs Outsourced RCM Services for Urology
 - 3.7.1 Community Practices
 - 3.7.2 Hospitals
- 3.8 Contract Agreement Framework
 - 3.8.1 Hospitals
 - 3.8.1.1 Medium-Sized Hospitals
 - 3.8.1.2 Large-Sized Hospitals
- 3.9 Impact of COVID-19 Pandemic on the U.S. Revenue Cycle Management for Oncology and Urology Market

CHAPTER 4 U.S. REVENUE CYCLE MANAGEMENT FOR ONCOLOGY AND UROLOGY MARKET: SOURCING MARKET ESTIMATES & TREND ANALYSIS

- 4.1 U.S. Revenue Cycle Management for Oncology and Urology Market: Sourcing Analysis
 - 4.1.1 In-House
 - 4.1.1.1 In-House market value estimates and forecasts, 2016 2030 (USD Billion)
 - 4.1.2 External RCM Apps/ Software
- 4.1.2.1 External RCM Apps/ Software market value estimates and forecasts, 2016 2030 (USD Billion)
 - 4.1.3 Outsourced RCM Services



4.1.3.1 Outsourced RCM Services market value estimates and forecasts, 2016 - 2030 (USD Billion)

CHAPTER 5 U.S. REVENUE CYCLE MANAGEMENT FOR ONCOLOGY AND UROLOGY MARKET: END-USE MARKET ESTIMATES & TREND ANALYSIS

- 5.1 U.S. Revenue Cycle Management for Oncology and Urology Market: End-Use Analysis
 - 5.1.1 Physicians and Clinical Services

5. PHYSICIANS AND CLINICAL SERVICES MARKET VALUE ESTIMATES AND FORECASTS, 2016 - 2030 (USD BILLION)

- 5.1.2 Hospitals
 - 5.1.2.1 Hospitals market value estimates and forecasts, 2016 2030 (USD Billion)

CHAPTER 6 U.S. REVENUE CYCLE MANAGEMENT FOR ONCOLOGY AND UROLOGY MARKET: COMPETITIVE ANALYSIS

- 6.1 Recent Developments & Impact Analysis, By Key Market Participants
- 6.2 Company Market Position Analysis
- 6.3 List of Key Competitors in Urology and Oncology with their Key Clientele

CHAPTER 7 COMPETITIVE LANDSCAPE

- 7.1 Company Profiles
 - 7.1.1 United Urology Group
 - 7.1.1.1 Company Overview
 - 7.1.1.2 Financial Performance
 - 7.1.1.3 Product Benchmarking
 - 7.1.1.4 Strategic Initiatives
 - 7.1.2 Cardinal Health
 - 7.1.2.1 Company Overview
 - 7.1.2.2 Financial Performance
 - 7.1.2.3 Product Benchmarking
 - 7.1.3 Flatiron
 - 7.1.3.1 Company Overview
 - 7.1.3.2 Financial Performance
 - 7.1.3.3 Product Benchmarking



- 7.1.3.4 Strategic Initiatives
- 7.1.4 Oncospark.com
 - 7.1.4.1 Company Overview
 - 7.1.4.2 Financial Performance
 - 7.1.4.3 Product Benchmarking
- 7.1.4.4 Strategic Initiatives
- 7.1.5 Fedora Solutions
 - 7.1.5.1 Company Overview
 - 7.1.5.2 Financial Performance
 - 7.1.5.3 Product Benchmarking
- 7.1.6 BillingParadise
 - 7.1.6.1 Company Overview
 - 7.1.6.2 Financial Performance
- 7.1.6.3 Product Benchmarking
- 7.1.7 Gentem
 - 7.1.7.1 Company Overview
 - 7.1.7.2 Financial Performance
 - 7.1.7.3 Product Benchmarking
- 7.1.7.4 Strategic Initiatives
- 7.1.8 Integra Connect, LLC
 - 7.1.8.1 Company Overview
 - 7.1.8.2 Financial Performance
 - 7.1.8.3 Product Benchmarking
 - 7.1.8.4 Strategic Initiatives
- 7.1.9 R1 RCM, Inc.
 - 7.1.9.1 Company Overview
 - 7.1.9.2 Financial Performance
 - 7.1.9.3 Product Benchmarking
 - 7.1.9.4 Strategic Initiatives



List Of Tables

LIST OF TABLES

- Table 1 Estimated total number of oncology hospitals and practices, 2021
- Table 2 Estimated total number of oncology hospitals and practices, by size, 2021
- Table 3 Estimated total number of urology hospitals and practices
- Table 4 Penetration rate of in-house vs outsourced RCM services for oncology in community practices (%)
- Table 5 Penetration rate of in-house vs outsourced RCM services for oncology in hospitals (%)
- Table 6 Penetration rate of in-house vs outsourced RCM services for urology in community practices (%)
- Table 7 Penetration rate of in-house vs outsourced RCM services for urology in hospitals (%)
- Table 8 Contract agreement framework in medium-sized hospitals
- Table 9 Contract agreement framework in large-sized hospitals



List Of Figures

LIST OF FIGURES

- Fig. 1 U.S. revenue cycle management for oncology and urology market segmentation
- Fig. 2 Market research process
- Fig. 3 Information procurement
- Fig. 4 Primary research pattern
- Fig. 5 Research methodology: U.S. RCM market
- Fig. 6 U.S. revenue cycle management for oncology and urology market trends & outlook
- Fig. 7 Penetration & growth prospect mapping
- Fig. 8 Market driver analysis (Current & future impact)
- Fig. 9 Market restraint analysis (Current & future impact)
- Fig. 10 U.S. revenue cycle management for oncology and urology market, sourcing outlook: Key takeaways (USD Billion)
- Fig. 11 U.S. revenue cycle management for oncology and urology market: Sourcing movement analysis (USD Billion)
- Fig. 12 In-house market estimates and forecasts, 2016 2030 (USD Billion)
- Fig. 13 External RCM apps/software market estimates and forecasts, 2016 2030 (USD Billion)
- Fig. 14 Outsourced RCM services market estimates and forecasts, 2016 2030 (USD Billion)
- Fig. 15 U.S. revenue cycle management for oncology and urology market, end-use outlook: Key takeaways (USD Billion)
- Fig. 16 U.S. revenue cycle management for oncology and urology market: End-use movement analysis (USD Billion)
- Fig. 17 Physicians and clinical services market estimates and forecasts, 2016 2030 (USD Billion)
- Fig. 18 Hospitals market estimates and forecasts, 2016 2030 (USD Billion)
- Fig. 19 Company market position analysis, 2022
- Fig. 20 Estimated share of in-house vs outsourced RCM solutions in oncology



I would like to order

Product name: U.S. Revenue Cycle Management for Oncology And Urology Market Size, Share &

Trends Analysis Report By Sourcing (In-house, External RCM Apps/ Software, Outsourced RCM Services), By End Use, And Segment Forecasts, 2023 - 2030

Product link: https://marketpublishers.com/r/UCF79A6250CBEN.html

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/UCF79A6250CBEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below



and fax the completed form to +44 20 7900 3970